| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 775 | 2021 |
| Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol T Reiberger, G Ulbrich, A Ferlitsch, BA Payer, P Schwabl, M Pinter, ... Gut 62 (11), 1634-1641, 2013 | 406 | 2013 |
| The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma W Sieghart, F Hucke, M Pinter, I Graziadei, W Vogel, C Müller, H Heinzl, ... Hepatology 57 (6), 2261-2273, 2013 | 376 | 2013 |
| Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy J Incio, H Liu, P Suboj, SM Chin, IX Chen, M Pinter, MR Ng, HT Nia, ... Cancer discovery 6 (8), 852-869, 2016 | 367 | 2016 |
| Astrocytic â2-adrenergic receptors mediate hippocampal long-term memory consolidation V Gao, A Suzuki, PJ Magistretti, S Lengacher, G Pollonini, MQ Steinman, ... Proceedings of the National Academy of Sciences 113 (30), 8526-8531, 2016 | 332* | 2016 |
| Cancer and liver cirrhosis: implications on prognosis and management M Pinter, M Trauner, M Peck-Radosavljevic, W Sieghart ESMO open 1 (2), e000042, 2016 | 268 | 2016 |
| Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy M Pinter, RK Jain Science translational medicine 9 (410), eaan5616, 2017 | 261 | 2017 |
| The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review M Pinter, RK Jain, DG Duda JAMA oncology 7 (1), 113-123, 2021 | 250 | 2021 |
| Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis M Pinter, W Sieghart, I Graziadei, W Vogel, A Maieron, R Königsberg, ... The oncologist 14 (1), 70-76, 2009 | 237 | 2009 |
| Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib M Pinter, F Hucke, I Graziadei, W Vogel, A Maieron, R Königsberg, ... Radiology 263 (2), 590-599, 2012 | 222 | 2012 |
| Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2 J Incio, JA Ligibel, DT McManus, P Suboj, K Jung, K Kawaguchi, M Pinter, ... Science translational medicine 10 (432), eaag0945, 2018 | 184 | 2018 |
| How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma F Hucke, M Pinter, I Graziadei, S Bota, W Vogel, C Müller, H Heinzl, ... Journal of hepatology 61 (6), 1287-1296, 2014 | 180 | 2014 |
| Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups M Pinter, B Scheiner, M Peck-Radosavljevic Gut 70 (1), 204-214, 2021 | 173 | 2021 |
| Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma N Rohr-Udilova, F Klinglmueller, R Schulte-Hermann, J Stift, M Herac, ... Scientific reports 8 (1), 6220, 2018 | 163 | 2018 |
| systemic treatment of hepatocellular carcinoma M Pinter, M Peck‐Radosavljevic Alimentary pharmacology & therapeutics 48 (6), 598-609, 2018 | 153 | 2018 |
| The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE F Hucke, W Sieghart, M Pinter, I Graziadei, W Vogel, C Müller, H Heinzl, ... Journal of Hepatology 60 (1), 118-126, 2014 | 151 | 2014 |
| Prognosis of patients with hepatocellular carcinoma treated with immunotherapy–development and validation of the CRAFITY score B Scheiner, K Pomej, MM Kirstein, F Hucke, F Finkelmeier, O Waidmann, ... Journal of hepatology 76 (2), 353-363, 2022 | 150 | 2022 |
| Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D¢Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 138 | 2022 |
| Non-selective â-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis T Reiberger, A Ferlitsch, BA Payer, M Pinter, M Homoncik, ... Journal of gastroenterology 47, 561-568, 2012 | 135 | 2012 |
| Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort B Scheiner, MM Kirstein, F Hucke, F Finkelmeier, K Schulze, J von Felden, ... Alimentary pharmacology & therapeutics 49 (10), 1323-1333, 2019 | 125 | 2019 |
